WEBULL

Takeda Pharmaceutical (TSE:4502) Taps Pharma.AI For Drug Discovery, Is The Stock Still Cheap?

Simply Wall St · 1d ago

Takeda Pharmaceutical (TSE:4502) has drawn fresh investor attention after agreeing to work with Insilico Medicine’s Pharma.AI platform, which ties its drug discovery pipeline more closely to artificial intelligence based molecule design.

See our latest analysis for Takeda Pharmaceutical.

The Pharma.AI collaboration lands at a time when Takeda Pharmaceutical’s share price has risen 8.5% year to date, while its 1-year total shareholder return of 26.82% points to solid long-term momentum, despite a softer 90-day share price return that declined 6.94%.

If this AI-driven approach to drug discovery has caught your attention, it could be a good moment to look across healthcare for other data focused opportunities using our 7 healthcare AI stocks

Taken together, Takeda Pharmaceutical’s strong 1 year run and recent pullback raise a simple issue: after this AI deal and the share price move, does the current valuation still offer an attractive balance of risk and reward for new buyers?

Most Popular Narrative: 13.1% Undervalued

Against Takeda Pharmaceutical’s last close of ¥5,334, the most followed narrative pegs fair value at ¥6,136.87. It frames the AI partnership within a broader recovery story driven by pipeline progress and earnings expectations.

The anticipated moderation and eventual stabilization of VYVANSE generic erosion after FY2025 will remove a major headwind for revenues, allowing Takeda's core growth and launch products to drive top-line and earnings recovery going forward.

Read the complete narrative.

Curious what earnings path, margin profile and future profit multiple have to look like to support that higher fair value tag? The narrative hinges on a measured revenue ramp, a meaningful uplift in profitability and a valuation multiple that sits well above the wider pharmaceuticals sector. If you want to see exactly how those ingredients combine into the ¥6,136.87 figure, the full narrative lays out each step of the thesis.

Result: Fair Value of ¥6,136.87 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Takeda Pharmaceutical story still carries real risk, particularly if generic competition bites harder than expected or late stage trials underperform current assumptions.

Find out about the key risks to this Takeda Pharmaceutical narrative.

Next Steps

If this mix of optimism and concern around Takeda Pharmaceutical leaves you undecided, it is worth acting soon to review the full picture yourself and weigh both sides using the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Takeda Pharmaceutical?

If Takeda Pharmaceutical has sharpened your focus on quality, use the Simply Wall St Screener to quickly surface other stocks that might suit your style and risk tolerance.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.